■为了描述司马鲁肽的作用,胰高血糖素样肽-1(GLP-1)激动剂,减轻超重或肥胖脊髓损伤(SCI)患者的体重并改善血糖控制。
■开放标签,随机药物干预病例系列。
本研究在JamesJ.PetersVA医疗中心(JJPVAMC)和Kessler康复研究所(KIR)进行。
■5名慢性SCI患者符合肥胖和碳水化合物代谢异常标准。
■施用司马鲁肽(每周一次皮下)与不治疗(对照)26周。
■总体重(TBW)的变化,脂肪组织质量(FTM),总脂肪百分比(TBF%),在基线和26周后使用双能X线吸收法测定内脏脂肪组织体积(VATvol);在相同的两个时间点获得空腹血糖(FPG)浓度和血清糖化血红蛋白(HbA1C)值。
■在3名参与者中,服用司马鲁肽26周后,TBW,FTM,TBF%,VATvol下降了,平均而言,由6,4.4公斤,1.7%,和674cm3,分别。此外,FPG和HbA1c值分别下降17mg/dl和0.2%,分别。在2名对照参与者中观察26周后,TBW,FTM,TBF%和VATvol平均增加3.3,4.5kg,2.5%,和991cm3,分别。FPG和HbA1c的平均值也增加了11mg/dl和0.3%,分别。
■26周服用司马鲁肽可使人体成分和血糖控制发生良好变化,提示有SCI的肥胖个体发生心脏代谢疾病的风险降低。试用注册:ClinicalTrials.gov标识符:NCT03292315。
UNASSIGNED: To describe the effect of semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, to reduce body weight and improve glycemic control in overweight or obese individuals with spinal cord injury (SCI).
UNASSIGNED: Open-label, randomized drug intervention
case series.
UNASSIGNED: This study was performed at James J. Peters VA Medical Center (JJP VAMC) and Kessler Institute for Rehabilitation (KIR).
UNASSIGNED: Five individuals with chronic SCI meeting criteria for obesity and abnormal carbohydrate metabolism.
UNASSIGNED: Administration of semaglutide (subcutaneously once per week) versus no treatment (control) for 26 weeks.
UNASSIGNED: Change in total body weight (TBW), fat tissue mass (FTM), total body fat percent (TBF%), and visceral adipose tissue volume (VATvol) was determined at baseline and after 26 weeks using Dual energy X-ray absorptiometry; fasting plasma glucose (FPG) concentration and serum glycated hemoglobin (HbA1C) values were obtained at the same two time points.
UNASSIGNED: In 3 participants, after 26 weeks of semaglutide administration, TBW, FTM, TBF%, and VATvol decreased, on average, by 6, 4.4 kg, 1.7%, and 674 cm3, respectively. In addition, values for FPG and HbA1c decreased by 17 mg/dl and 0.2%, respectively. After 26 weeks of observation in the 2 control participants, TBW, FTM, TBF% and VATvol increased on average by 3.3 , 4.5 kg, 2.5%, and 991 cm3, respectively. The average values for FPG and HbA1c also increased by 11 mg/dl and 0.3%, respectively.
UNASSIGNED: Administration of semaglutide for 26 weeks resulted in favorable changes in body composition and glycemic control, suggesting a reduced risk for the development of cardiometabolic disease in obese individuals with SCI.Trial registration: ClinicalTrials.gov identifier: NCT03292315.